Your browser doesn't support javascript.
loading
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
Brighton, Timothy A; Khot, Amit; Harrison, Simon J; Ghez, David; Weiss, Brendan M; Kirsch, Andres; Magen, Hila; Gironella, Mercedes; Oriol, Albert; Streetly, Matthew; Kranenburg, Britte; Qin, Xiang; Bandekar, Rajesh; Hu, Peter; Guilfoyle, Mary; Qi, Ming; Nemat, Sepideh; Goldschmidt, Hartmut.
Afiliação
  • Brighton TA; Prince of Wales Hospital, Randwick, New South Wales, Australia.
  • Khot A; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Harrison SJ; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Ghez D; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
  • Weiss BM; Service d'Hématologie, Département de Médecine, Gustave Roussy Cancer Campus, Villejuif, France.
  • Kirsch A; Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Magen H; Medizinisches Versorgungszentrum Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany.
  • Gironella M; Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Oriol A; Haematology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Streetly M; Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Kranenburg B; Clinical Haematology, Guys Hospital, Guys and St. Thomas' NHS Foundation Trust, London, United Kingdom.
  • Qin X; Janssen Biologics BV, Leiden, Netherlands.
  • Bandekar R; Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • Hu P; Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • Guilfoyle M; Janssen Research & Development, LLC, Raritan, New Jersey.
  • Qi M; Janssen Research & Development, LLC, Raritan, New Jersey.
  • Nemat S; Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • Goldschmidt H; Janssen-Cilag Ltd, High Wycombe, United Kingdom.
Clin Cancer Res ; 25(13): 3772-3775, 2019 07 01.
Article em En | MEDLINE | ID: mdl-30890552
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia de Alvo Molecular / Mieloma Múltiplo Latente / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia de Alvo Molecular / Mieloma Múltiplo Latente / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália